Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
120.5 USD | +1.14% | +0.05% | +7.37% |
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With a 2024 P/E ratio at 24.11 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.37% | 6.73B | B- | ||
-24.78% | 15.28B | B+ | ||
-1.80% | 11.78B | B | ||
+3.15% | 11.66B | B+ | ||
+8.14% | 10.5B | B+ | ||
+27.97% | 8.52B | B | ||
-8.55% | 7.35B | A- | ||
+9.48% | 6.51B | D | ||
-2.44% | 4.33B | - | ||
+11.67% | 4.24B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ENSG Stock
- Ratings The Ensign Group, Inc.